Drugs / Yangzhengxiaoji
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05641506 | Dec 2022 → Oct 2023 | ovarian cancer | Sichuan Cancer Hospital and Research Institute | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02195453 | Aug 2014 → Sep 2016 | non-small cell lung carcinoma | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yangzheng Xiaoji | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05641506 ↗ |
| Known as | Yangzheng Xiaoji capsule | “Chinese patent medicine Yangzheng Xiaoji capsule， 0.36g\*4 tid，28 days as one cycle，up to 3 cycles.” NCT05641506 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Chinese patent medicine Yangzheng Xiaoji capsule， 0.36g\*4 tid，28 days as one cycle，up to 3 cycles.” NCT05641506 ↗ |
| Route | Oral | “Yangzhengxiaoji Capsule four granules t.i.d po” NCT02195453 ↗ |